撰文丨王聪 该研究开发了 按需挤出 （ extrusion-on-demand， EoD ） 生物打印技术，构建出具有微米级结构保真度 （内膜、中膜和外膜） 与可定制宏观 几何形状的 动脉模型 ，再现了血管疾病中的协同微环境相互作用， 可用于解析心血管疾 病机制、评估微环境特异性疗法，从而推动心血管疾病的个性化治疗革新。 编辑丨王多鱼 排版丨水成文 心血管疾病 是全球头号致死病因，然而，由于缺乏能够真实再现人体动脉复杂环境的实验室模型，预防和治 疗心血管疾病的研究一直受阻。在患者身上，血管疾病是由结构重塑、血流紊乱和炎症信号转导等多种因素 共同作用而产生的，但现有的模型却过于简化了这一现实。二维 （2D） 平面培养无法体现细胞间相互作 用，而大多数三维 （3D） 系统又缺乏天然血管所具有的分层结构和血流动力学调控机制。因此，许多基本 机制仍未得到解决，药物试验也常常无法取得预期效果。 2025 年 11 月 11 日，浙江大学 杨华勇 院士团队 周竑钊 、西湖大学 沈璐琦 、杭州师范大学 李琦 作为共同通讯作者，在 Cell 子刊 Cell Biomaterials 上发表了题为： Multiscale bi ...

Group 1: Biomedical Engineering Innovations - Recent advancements in biomedical engineering are reshaping the future of health, with innovations such as 3D printed organs and smart prosthetics [3][12] - In June 2025, a research team in China discovered a "molecular switch" for mammalian organ regeneration, enabling injured adult mice to regrow ear cartilage and nerve tissue [1] - The world's first living heart organoid, over 1 centimeter in diameter, was successfully cultivated in Shanghai, derived from human stem cells, offering new hope for organ transplantation [1][4] Group 2: Organoid Technology and Applications - Organoids are miniaturized organ models created from stem cells that can simulate real organ structures and functions, useful for disease modeling and drug screening [4][11] - The process of 3D printing active organoids requires billions of cells, with advancements in bioprinting technology allowing for the creation of complex structures [5][9] - Current applications include printing skin, cartilage, and small organoids for clinical use, while more complex organ printing is still in research stages [11][12] Group 3: Drug Testing and Personalized Medicine - High-throughput organoid printing technology allows for the simulation of cancer patient tumors, enabling efficient drug testing without the need for blind trials on patients [14] - This method allows for simultaneous testing of multiple drugs and dosages, streamlining the process of finding effective treatment options [14] Group 4: Cross-Disciplinary Collaborations - Recent developments in vision prosthetics demonstrate the potential of interdisciplinary collaboration, with a team creating a wide-spectrum visual prosthetic that enables blind animals to perceive infrared light [17][18] - The project involved multiple national key laboratories, showcasing a new paradigm of innovation in biomedical engineering through cross-laboratory cooperation [24] Group 5: Strategic Industry Development - Shanghai has initiated an innovation ecosystem for organoids since 2021, focusing on drug screening and personalized medicine [26] - Hubei aims to grow its biopharmaceutical industry to 250 billion by 2027, emphasizing organoid technology as a key direction [26] - Shenzhen has included cutting-edge fields like cell therapy and gene therapy in its support measures for the pharmaceutical and medical device sectors [26]